ReviewNature reviews. Cardiology2015
Use of medication for cardiovascular disease during pregnancy.
Review in Nature reviews. Cardiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 82 citations in OpenAlex.
- Pregnancy in Women With Impaired Left Ventricular Function: Data From ROPAC.JACC. Advances · 2026Article
- Fetal Supraventricular Tachycardia: What Do We Know up to This Day?Journal of personalized medicine · 2025Review
- Mechanical tricuspid valve thrombosis in pregnancy: a case report and literature review on anticoagulation challenges and fetal protection strategies.Frontiers in pediatrics · 2025Article
- Role of Transcatheter Structural Interventions in Pregnant Women.Interventional cardiology (London, England) · 2025Review
- Pre-existing maternal cardiovascular disease and the risk of offspring cardiovascular disease from infancy to early adulthood.European heart journal · 2024Article
- The Pathophysiology, Prognosis and Treatment of Hypertension in Females from Pregnancy to Post-menopause: A Review.Current heart failure reports · 2024Review
- Disease features and management of cardiomyopathies in women.Heart failure reviews · 2024Review
- Spontaneous pregnancy-associated coronary artery dissection: a case report on diagnostic and therapeutic challenges.European heart journal. Case reports · 2024Article
- Contemporary Management of Cardiomyopathy and Heart Failure in Pregnancy.Cardiology and therapy · 2024Review
- Association of pre-existing maternal cardiovascular diseases with neurodevelopmental disorders in offspring: a cohort study in Sweden and British Columbia, Canada.International journal of epidemiology · 2024Article
- Balancing Hemostasis With Thrombosis: A Challenging Case of Pregnancy With a Mechanical Mitral Valve.JACC. Case reports · 2024Article
- Case report: A pregnant woman accidental treated with spironolactone in mid-gestation.Frontiers in pharmacology · 2024Article
- International Atherosclerosis Society guidance for implementing best practice in the care of familial hypercholesterolaemia.Nature reviews. Cardiology · 2023Review
- The Challenge of Managing Atrial Fibrillation during Pregnancy.Reviews in cardiovascular medicine · 2023Review
- Pregnant and lactating women should be included in clinical trials for cardiovascular disease.Nature medicine · 2023Article
- Severe maternal morbidity and mortality during the COVID-19 pandemic: a cohort study in Rio de Janeiro.IJID regions · 2023Article
- The multidisciplinary management of a mechanical mitral valve thrombosis in pregnancy: a case report and review of the literature.European heart journal. Case reports · 2022Article
- Maternal beta-blocker dose and risk of small-for gestational-age in women with heart disease.Acta obstetricia et gynecologica Scandinavica · 2022Article
- Management of percutaneous treatment of aorta coarctation diagnosed during pregnancy.Journal of medicine and life · 2022Article
- Management of pregnant patients with pulmonary arterial hypertension.Frontiers in cardiovascular medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
One-third of women with heart disease use medication for the treatment of cardiovascular disease (CVD) during pregnancy. Increased plasma volume, renal clearance, and liver enzyme activity in pregnant women change the pharmacokinetics of these drugs, often resulting in the need for an increased dose. Fetal well-being is a major concern among pregnant women. Fortunately, many drugs used to treat CVD can be used safely during pregnancy, with the exception of high-dose warfarin in the first trimester, angiotensin-converting-enzyme inhibitors, angiotensin-receptor blockers, amiodarone, and spironolactone. A timely and thorough discussion between the cardiologist and the pregnant patient about the potential benefits and adverse effects of medication for CVD is important. Noncompliance with necessary treatment for cardiovascular disorders endangers not only the mother, but also the fetus. This Review is an overview of the pharmacokinetic changes in medications for CVD during pregnancy and the safety of these drugs for the fetus. The implications for maternal treatment are discussed. The Review also includes a short section on the cardiovascular effects of medication used for obstetric indications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.